Alzheimer CSF biomarkers in routine clinical setting
Acta Neurologica Scandinavica, 05/07/2012Tabaraud F et al.
The interest of biomarkers and their ability to solve awkward cases were carefully noticed all the more when a discrepancy between clinical and cerebrospinal fluid biomarkers (CSF) biological data was involved. The final proposed algorithm allowed to identify pathogenic forms of AD according to the prevailing role of hyperphosphorylated tau or amyloid beta peptide.
For this purpose, 150 patients clinically and neurochemically classified as having AD or cognitive impairment with or without other dementia type were included in the study.
The following CSF peptides were studied, blindly to the clinical diagnosis: beta-amyloid1–42 peptide (Aβ1–42), Tau (T-tau), threonine-181 hyperphosphorylated tau protein (P-tau181), and beta-amyloid1–40 peptide (Aβ1–40).
From these measurements, Innotest Amyloid Tau Index (IATI) was calculated for each patient.
This assessment allowed to separate 83 biochemical profiles of AD and 67 non-Alzheimer’s disease (non-AD), both AD and non-AD categories match with clinical data amounting to 73% and 90%, respectively.
Among mild cognitive impairment (MCI) patients, CSF biomarkers led to discriminate those who are likely to be AD.
The authors devoted a special section to Aβ1–40 which is not a routine parameter but can help to confirm a pathological amyloid process as Aβ1–42/Aβ1–40 ratio underlining the real decline of the Aβ1–42.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.